This study refines ibrutinib’s target landscape by resolving drug targets while accounting for functional proteoform groups, identifying off-targets linked to immunomodulation and cellular processes and identifying variability in CLL patient responses, establishing a framework to understand drug interactions in precision medicine.
- Isabelle Rose Leo
- Elena Kunold
- Rozbeh Jafari